anti-her2 therapy for breast cancer ana lilia castruita-avila, m.d.
Published 5 years ago • 443 plays • Length 12:40Download video MP4
Download video MP3
Similar videos
-
3:01
adjuvant endocrine therapy and risk of contralateral breast cancer
-
2:33
who should receive combination therapy for er positive breast cancer?
-
0:45
dr. hamilton on using pcr to classify risk in her2 breast cancer
-
1:47
evaluating the role of neoadjuvant endocrine therapy in breast cancer
-
1:03
is there any alternative treatment for breast cancer? - dr. nanda rajaneesh
-
3:41
diagnosis of her2 /er- early breast cancer
-
1:27
treating er breast cancer patients with endocrine therapy resistance
-
2:33
challenges with neoadjuvant endocrine therapy in breast cancer
-
8:30
hr breast cancer: endocrine therapy, surgery and radiotherapy
-
0:41
dr. freedman discusses dual her2-targeted therapy in breast cancer
-
1:49
dr. rahman on pertuzumab and neratinib in her2 breast cancer
-
4:01
duration of endocrine therapy in breast cancer
-
0:16
perjeta approved for neoadjuvant breast cancer treatment
-
2:49
her2-e pcr with anti-her2-based neoadjuvant therapies
-
15:51
considerations for pre-operative therapy to optimize care of women with her2 breast cancer
-
2:22
types of anti-estrogen therapy
-
2:03
dr. lori goldstein on neoadjuvant treatment for her2 breast cancer
-
4:56
neoadjuvant talazoparib active in brca-mutated early breast cancer | jennifer litton
-
1:37
dr rita nanda on using precision medicine to scale back on chemotherapy treatments in breast cancer